![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, May 12, 2020 11:09:33 AM
GLTA
Recent ESPR News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/17/2024 07:22:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/17/2024 07:11:07 PM
- New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries • GlobeNewswire Inc. • 07/16/2024 12:00:00 PM
- Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility • GlobeNewswire Inc. • 06/28/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/18/2024 07:19:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/18/2024 07:09:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:16:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:18:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:14:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:13:07 PM
- Esperion to Participate in Upcoming June Investor Conferences • GlobeNewswire Inc. • 05/23/2024 01:00:00 PM
- First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk • GlobeNewswire Inc. • 05/22/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 08:14:43 PM
- Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia • GlobeNewswire Inc. • 05/20/2024 10:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 07:08:17 PM
- Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® • GlobeNewswire Inc. • 05/14/2024 12:00:00 PM
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/10/2024 08:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:31:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 12:50:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:29:53 AM
- Esperion Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/07/2024 10:00:00 AM
- Esperion to Participate in Upcoming May Investor Conferences • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Esperion to Report First Quarter 2024 Financial Results on May 7 • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity • GlobeNewswire Inc. • 04/07/2024 06:45:00 PM
- Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
FEATURED Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM